Qtron Investments LLC lowered its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 15.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 35,765 shares of the company's stock after selling 6,750 shares during the quarter. Qtron Investments LLC's holdings in Novo Nordisk A/S were worth $3,077,000 at the end of the most recent reporting period.
Several other large investors have also recently modified their holdings of the company. Rockefeller Capital Management L.P. grew its position in Novo Nordisk A/S by 2.7% during the fourth quarter. Rockefeller Capital Management L.P. now owns 497,667 shares of the company's stock valued at $42,868,000 after buying an additional 13,081 shares during the period. Texas Capital Bancshares Inc TX boosted its holdings in shares of Novo Nordisk A/S by 12.9% during the 4th quarter. Texas Capital Bancshares Inc TX now owns 3,210 shares of the company's stock worth $276,000 after purchasing an additional 366 shares during the last quarter. Kennedy Capital Management LLC acquired a new position in shares of Novo Nordisk A/S during the 4th quarter valued at about $2,023,000. Scotia Capital Inc. increased its holdings in shares of Novo Nordisk A/S by 2.1% during the 4th quarter. Scotia Capital Inc. now owns 285,791 shares of the company's stock worth $24,586,000 after buying an additional 5,833 shares during the last quarter. Finally, Phoenix Financial Ltd. lifted its stake in shares of Novo Nordisk A/S by 37.5% in the 4th quarter. Phoenix Financial Ltd. now owns 19,140 shares of the company's stock valued at $1,647,000 after purchasing an additional 5,220 shares during the last quarter. Institutional investors own 11.54% of the company's stock.
Wall Street Analysts Forecast Growth
NVO has been the topic of a number of recent research reports. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. UBS Group upgraded shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. BMO Capital Markets dropped their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a research report on Monday, December 23rd. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research note on Monday, January 6th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $145.25.
Read Our Latest Stock Analysis on Novo Nordisk A/S
Novo Nordisk A/S Trading Down 1.0 %
NVO stock traded down $0.67 during mid-day trading on Wednesday, reaching $63.82. 3,874,971 shares of the stock traded hands, compared to its average volume of 5,826,943. The stock's fifty day moving average is $77.02 and its 200-day moving average is $92.75. The company has a market cap of $286.39 billion, a P/E ratio of 19.40, a P/E/G ratio of 0.90 and a beta of 0.61. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 52-week low of $59.32 and a 52-week high of $148.15.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.
Novo Nordisk A/S Increases Dividend
The company also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were paid a $0.7874 dividend. This represents a yield of 1.2%. The ex-dividend date was Monday, March 31st. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio is presently 49.54%.
About Novo Nordisk A/S
(
Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Further Reading
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
